Dr. Rami Batniji analyzes how the Cold Technology manufacturing process of Evolyse can offer clinical advantages over traditional landfills of hyaluronic acid.
As a new injectable enters the United States aesthetics market, plastic surgeons are analyzing more closely how their formulation can differ from the established options. Evolysse is a landfill of hyaluronic acid developed with cold technology, an approach designed to reduce the BDDE content and replicate more closely natural ones. Early clinical data suggest possible advantages in terms of efficiency, swelling and immune response.
For more information on how this product can fit into treatment plans, Practice of Plastic Surgery He spoke with Persana’s Network doctor, Rami Batniji, MD. Batniji, a facial plastic surgeon certified by the Board in Newport Beach, California, shares its ideas about the clinical performance of Evsinsse and how it compares with other Ha fillings in use today.
Practice of Plastic Surgery: What should plastic surgeons know about evolution when entering the United States injectable market and how compared to existing hyaluronic acid fillings?
Rami Batniji, MD: Evolysse is the first of injectable hyaluronic acid gel developed with cold technology. Through this unique manufacturing process, there are fewer amounts of BDDE (1.4 butredoil ether), which is important because there is a group that BDDE in the fillings can be immunostimulant and result in certain molars. In addition, cold technology allows a longer chain hyaluronic acid gel in the evolution and its longer chains that are more common in nature and, therefore, behave more similar to natural hyaluronic acid.
PSP: From a clinical perspective, what stands out on the formulation or performance of Evsinsse in the modato of treatment to severe wrinkles such as nasolabial folds?
Batniji: Evolisse has very low hydrophilic characteristics, which means that less swelling is caused with this gel of hyaluronic acid compared to others. As such, the injections must be made for complete correction and “what you see is what you get” at the end of the procedure. It is also very efficient; The studies showed that this product tested a better correction with minor amounts of injected products.
PSP: Are there particular objectives of patients or aesthetic objectives that make some strong candidates for evolution about other Ha fillings?
Batniji: All patients who are candidates for hyaluronic acid injections would be appropriate candidates for evolution.
PSP: What has been your experience with your experience with the satisfaction of the patient and the longevity of the results with Evolysse so far?
Batniji: According to the study that was integral to achieve the FDA approach for evolution, patient satisfaction was very high and the duration was comparable to other hyaluronic acid fillings currently available in the US market.
PSP: How do you see evolysis in or remodel current treatment plans, particularly in combination with other injectables or surgical procedures?
Batniji: In this current environment, less is more with hyaluronic acid fillings. Suppliers and patients because natural results with less product. Evolysse has proven efficient, which means that the results can be achieved with less product. It also has a leg show to be more natural; It consists of longer chain hyaluronic acid that is similar to what we see in nature. And it has less BDDD, which can lead to less immune problems of medium socks as well as the sea of legs with other landfills of hyaluronic acid. The cold technology manufacturing process allows the unique characteristic thesis of EVOLYSSE. PSP
Main photo: Evolysee
